Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Reports 9.2-Percent Increase in Q4 Revenues

NEW YORK, Feb. 9 (GenomeWeb News) - Sigma-Aldrich yesterday reported net sales of $352 million in the fourth quarter of 2004, up 9.2 percent from $322 million in the same period in 2003.


The increase was bolstered by a 4.8-percent currency gain, Sigma said, as well as contributions from Ultrafine and Tetrionics, which Sigma acquired in Q2 of 2004. Approximately one-half of Sigma's sales are in currencies other than dollars, and its revenues reflect benefits from exchange rates.


Revenues in Sigma's biotechnology unit spiked to $76.2 million in Q4 2004 from $72.6 million in Q4 2003.


Sigma recorded a gross profit of $187.4 million last quarter, up from $168.9 million in the year-ago period. Sigma's R&D expenses remained steady between Q4 2004 and 2003 at $11.1 million.


The St. Louis-based firm reported $169.2 million in cash and cash equivalents as of Dec. 31, 2004.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.